TAFASITAMAB
UNII QQA9MLH692

Substance Identification & Data

This profile provides standardized clinical and technical data for Tafasitamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) QQA9MLH692.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1422527-84-1 and the RxNorm Concept ID (RxCUI) 2387211. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

QQA9MLH692

CAS Registry Number

1422527-84-1

RxNorm Concept ID

2387211

Detailed Substance Profile

Preferred Name

TAFASITAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

QQA9MLH692

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C95768

National Cancer Institute reference terminology for clinical and research data.

INN ID

10835

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-86

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tafasitamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TAFASITAMAB

TAFASITAMAB-CXIX

Common Names & Synonyms

HUMANIZED FC ENGINEERED MONOCLONAL ANTIBODY AGAINST CD19

IMMUNOGLOBULIN, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL MOR00208 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MOR00208 .KAPPA.-CHAIN, DIMER

MOR-208

TAFASITAMAB [INN]

TAFASITAMAB [MI]

TAFASITAMAB [USAN]

TAFASITAMAB [WHO-DD]

TAFASITAMAB CXIX [WHO-DD]

XMAB5574

XMAB-5574